Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from PYPD

PolyPid Q1 Earnings Call Highlights

PolyPid (NASDAQ:PYPD) said its first quarter marked a transition from late-stage clinical development toward regulatory submission and commercial preparation for D-PLEX100, its lead product candidate for preventing surgical site infections in abdominal colorectal surgery. Chief Executive Officer Di

MarketBeat · May 13

Why PolyPid Shares Are Gaining Today

Why PolyPid Shares Are Gaining Today

The independent Data Safety Monitoring Board (DSMB) has recommended concluding enrollment in PolyPid Ltd's (NASDAQ:PYPD) SHIELD I Phase 3 study of D-PLEX100 to prevent surgical site infections (SSIs) abdominal tissue surgery. DSMB recommended stopping enrollment upon 950 patients, which is the minimum number of targeted patients in the study protocol The suggestion follows the…

Benzinga · May 23, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

1

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

430,920 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play